SurVaxM

MimiVax's Phase 2b SURVIVE trial for SurVaxM in newly diagnosed glioblastoma patients has successfully passed its first interim analysis, allowing the study to continue as planned.

New therapeutic approaches, including small molecules, cell therapies, and vaccines, are revitalizing glioblastoma research after 20 years of limited progress.

SurVaxM, a brain cancer vaccine developed at Roswell Park, has shown promising results in adults by doubling survival time in glioblastoma patients.

Roswell Park Comprehensive Cancer Center has launched the SURVIVE trial, a phase 2B randomized study evaluating SurVaxM immunotherapy in 265 newly diagnosed glioblastoma patients.